Lower-Dose Tamoxifen Works As Well As High-Dose
New research shows that a lower dose of the hormone therapy Tamoxifen is as effective as the higher dose treatment in helping to prevent breast cancer from returning and guarding against new cancers in women who had high-risk breast tissue. (Source: WebMD Health)
Source: WebMD Health - December 6, 2018 Category: Consumer Health News Source Type: news
Tamoxifen at a Lower Dose Might Still Prevent Breast Cancer ’ s Return
(Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - December 6, 2018 Category: Cancer & Oncology Tags: Endocrinology, Gynecology, Nursing, Oncology, Pharmacy, News, Source Type: news
Tamoxifen at a Lower Dose Might Still Prevent Breast Cancer's Return
THURSDAY, Dec. 6, 2018 -- Tamoxifen is considered a vital weapon in the fight against breast cancer, but many women who have to take the drug struggle with its significant side effects.
Now, new research shows that a lower dose of the hormone... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - December 6, 2018 Category: General Medicine Source Type: news
SABCS: Low-Dose Tamoxifen Cuts Risk for Breast Dz
THURSDAY, Dec. 6, 2018 -- Tamoxifen at a dose of 5 mg/day is associated with a reduced risk for recurrence for women with hormone-sensitive breast intraepithelial neoplasia, according to a study presented at the annual San Antonio Breast Cancer... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - December 6, 2018 Category: Pharmaceuticals Source Type: news
Low-dose tamoxifen reduced recurrence and new disease for patients with DCIS, LCIS, and ADH
(American Association for Cancer Research) Treatment with a low dose of tamoxifen (5 mg per day) halved the risk of disease recurrence and new disease for women who had been treated with surgery following a diagnosis of breast intraepithelial neoplasia compared with placebo, and it did not cause more serious adverse events, according to data from the randomized, phase III TAM-01 clinical trial presented at the 2018 San Antonio Breast Cancer Symposium. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - December 6, 2018 Category: Cancer & Oncology Source Type: news
Tamoxifen at a Lower Dose Might Still Prevent Breast Cancer's Return
(Source: Cancercompass News: Breast Cancer)
Source: Cancercompass News: Breast Cancer - December 6, 2018 Category: Cancer & Oncology Source Type: news
Tamoxifen at a Lower Dose Might Still Prevent Breast Cancer's Return
(Source: Cancercompass News: Other Cancer)
Source: Cancercompass News: Other Cancer - December 6, 2018 Category: Cancer & Oncology Source Type: news
Adding Metformin to Tamoxifen to Protect the Endometrium Adding Metformin to Tamoxifen to Protect the Endometrium
Might the addition of metformin help mitigate the endometrial effects of tamoxifen therapy?Clinical Endocrinology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - December 3, 2018 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news
A molecule for fighting muscular paralysis
(Universit é de Gen è ve) Myotubular myopathy is a severe genetic disease that leads to muscle paralysis. Although no treatment currently exists, researchers from the UNIGE-with the University of Strasbourg,- have identified a molecule that not only greatly reduces the progression of the disease but also boosts life expectancy in animal models by a factor of seven. Since the molecule -- known as tamoxifen -- is already used for breast cancer, the researchers hope to soon set up a clinical trial. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - November 19, 2018 Category: International Medicine & Public Health Source Type: news
This Combo Improves Outcomes Over Tamoxifen in Early Breast Cancer
New drug combo offers improved disease-free survival in patients with hormone receptor (HR)-positive early breast cancer. (Source: CancerNetwork)
Source: CancerNetwork - November 7, 2018 Category: Cancer & Oncology Authors: Dave Levitan Source Type: news
Zoledronic acid improves disease-free survival in premenopausal HR+ early breast cancer
(European Society for Medical Oncology) Adjuvant treatment with the bone sparing drug zoledronic acid plus hormonal therapy with the aromatase inhibitor letrozole significantly increases disease-free survival compared to tamoxifen in premenopausal women with hormone receptor positive (HR+) early breast cancer, according to results reported at ESMO 2018 Congress in Munich. It is the first study to assess this specific combination in premenopausal breast cancer and adds to previous observations with zoledronic acid and anastrozole in premenopausal women receiving ovarian suppression. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - October 22, 2018 Category: Cancer & Oncology Source Type: news
RT Add-On Boosts Outcomes in'Low-Risk' DCIS Breast Ca
(MedPage Today) -- Highest benefit seen in patients who also used tamoxifen (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - October 22, 2018 Category: Hematology Source Type: news
Recognizing Nonadherence to Tamoxifen in Early Breast Cancer Patients
In premenopausal patients with early breast cancer, approximately one-sixth are not adequately adherent to adjuvant endocrine therapy. (Source: CancerNetwork)
Source: CancerNetwork - October 19, 2018 Category: Cancer & Oncology Authors: Dave Levitan Source Type: news
One in six premenopausal early breast cancer patients do not adhere to hormonal therapy
(European Society for Medical Oncology) Nearly one in six premenopausal women being treated for early stage breast cancer do not adhere adequately to tamoxifen therapy after one year of treatment, potentially putting themselves at increased risk of recurrence and reduced survival, a French prospective study reports at ESMO 2018. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - October 18, 2018 Category: Cancer & Oncology Source Type: news
Cancer drug and antidepressants provide clues for treating brain-eating amoeba infections
(University of California - San Diego) Researchers at Skaggs School of Pharmacy and Pharmaceutical Sciences at University of California San Diego have now identified three new molecular drug targets in Naegleria fowleri and a number of drugs that are able to inhibit the amoeba's growth in a laboratory dish. Several of these drugs are already approved by the US Food and Drug Administration for other uses, such as antifungal agents, the breast cancer drug tamoxifen and antidepressant Prozac. (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - September 13, 2018 Category: Infectious Diseases Source Type: news
